Accelerate Your Breakthrough Discoveries with Enhanced BOND RX & Nanostring GeoMx Automated RNA Digital Spatial Profiling
SEATTLE, USA and MELBOURNE, AUSTRALIA. March 1st Leica Biosystems continues to advance its relationship with NanoString Technologies Inc., supporting translational research to build confidence in reproducibility and throughput while minimizing manual steps and reducing hands-on time with the release of the fully automated GeoMx RNA protocol on BOND RX and BOND RXm research staining systems.
“This fully automated protocol not only increased our ability to get more slides done in a week but also increased the quality of the data coming off of our instrument by reducing variability between runs,” said Carlee Hemphill, lead scientist, CDx Labcorp Drug Development.
NanoString's GeoMx Digital Spatial Profiler uses spatial images, chemistry, and workflow to enable high-plex profiling of regions of interest without destruction of tissue. GeoMx DSP is the only technology that simultaneously performs high-plex profiling and imaging on a single 5μm tissue section.
BOND RX, a fully automated Leica Biosystems research staining solution, offers an open platform that enables investigators’ flexibility in developing customized protocols for IHC, ISH, and emerging technologies with open reagents and detection options. The improved and flexible RNA protocol offers whole transcriptome profiling adaptability to any tissue. Combining the power of GeoMx DSP technology with BOND RX automated workflow, it delivers researchers a high throughput, spatially resolved, high-plex RNA profiling solution.
The integration of BOND RX into the GeoMx DSP workflow automates translational research sample processing - helping researchers unveil the function of cell populations by bringing together tissue morphological context and high-plex RNA expression profiling from a single slide sample.
“Scientists are increasingly examining the spatial organization and architecture of biomarkers within tissues to explore linkages between biology and cancer progression”; said Colin White PhD Senior Vice President of Advanced Staining and Imaging at Leica Biosystems. By collaborating with NanoString, we are delighted to provide an easy-to-use system that elevates productivity in generating spatial signatures. Thereby, accelerating the quest of researchers to deepen knowledge of the tumor microenvironment.
“We’re excited to have the Leica Biosystems workflow as part of our spatial biology ecosystem,” said Vice President of Marketing for NanoString, Anna Berdine. “Enabling full automation facilitates translational and multi-sample studies by improving reproducibility and decreasing the hands-on time down to one hour, freeing up researchers to focus more of their time on generating insights from their data.”
For research use only. Not for use in diagnostic procedures
About Leica Biosystems
Leica Biosystems is a cancer diagnostics company and a global leader in workflow solutions. Only Leica Biosystems offers the most comprehensive portfolio that spans the entire workflow from biopsy to diagnosis. With unique expertise, we are dedicated to driving innovations that connect people across radiology, pathology, surgery and oncology. Our experts are committed to delivering Improved Quality, Integrated Solutions, and Optimized Efficiencies leading to breakthrough advances in diagnostic confidence. Our mission of "Advancing Cancer Diagnostics, Improving Lives" is at the heart of our corporate culture. Visit LeicaBiosystems.com for more information.
About NanoString Technologies, Inc.
NanoString Technologies is a leading provider of life science tools for discovery and translational research. The company provides three platforms that allow researchers to map the universe of biology. The nCounter® Analysis System, cited in more than 5,000 peer-reviewed publications, offers a way to easily profile the expression of hundreds of genes, proteins, miRNAs, or copy number variations, simultaneously with high sensitivity and precision. NanoString’s GeoMx® Digital Spatial Profiler enables highly multiplexed spatial profiling of RNA and protein targets in various sample types, including FFPE tissue sections, and has been cited in more than 90 peer-reviewed publications. The CosMx™ Spatial Molecular Imager, with commercial availability expected in 2022, enables highly sensitive, high-resolution imaging of hundreds to thousands of RNAs or proteins directly from single cells within morphologically intact whole tissue sections. For more information, visit www.nanostring.com.
